Eduovisual
Ethics, Communication & Professionalism
Conflicts of interest and gifts from industry
— Pharmaceutical and device manufacturer gifts, meals, travel, speaker fees, consulting honoraria, research funding, royalties, and equity stakes
— Drug samples, sponsored CME, ghostwritten manuscripts, and "key opinion leader" arrangements
— Even small gifts (pens, lunches) demonstrably shift prescribing behavior — the size of the gift does not predict the size of the bias
— Vignette mentions a drug rep visit, sponsored dinner, free samples, paid speaker engagement, or stock ownership in a company whose product the physician prescribes/studies
— Researcher receives funding from a company whose drug is being studied
— Physician owns an imaging center or surgicenter and refers patients there (self-referral)
— Family member employed by or invested in a relevant company
— Physician Payments Sunshine Act (2010, ACA): manufacturers must report payments/transfers of value ≥$10 (or aggregate >$100/yr) to physicians and teaching hospitals — published on CMS Open Payments database
— Stark Law: prohibits physician self-referral for designated health services to entities with which they have a financial relationship (Medicare/Medicaid)
— Anti-Kickback Statute: criminalizes remuneration intended to induce referrals
— AMA, ACP, AAMC, and PhRMA Code: discourage gifts of more than nominal value; meals only with educational content; no entertainment, travel, or recreational gifts
Board pearl: On Step 3, the correct answer to "Should I accept this?" is almost always decline or disclose, never "accept because it's small" or "accept because it won't affect my judgment." The exam treats self-assessed objectivity as unreliable.
— A pharmaceutical representative offers lunch for the office staff while discussing a new anticoagulant
— An orthopedic device company invites the surgeon to a "training weekend" at a resort, expenses paid
— A clinical trial sponsor offers the PI stock options in addition to per-patient enrollment fees
— A grateful patient (or industry contact) offers concert tickets, a vacation, or cash
— A residency program director is offered an unrestricted educational grant tied to inviting a specific speaker
— Magnitude: nominal (<$10 pens, textbooks of patient-care value) vs substantial (travel, equity, large honoraria)
— Educational vs promotional: independent CME with no sponsor input on content is generally acceptable; promotional dinners with scripted slides are not
— Decision-making power: is the physician on a formulary committee, guideline panel, IRB, or purchasing committee? Threshold for refusal is markedly lower
— Direct patient impact: does accepting the gift influence prescribing, referral, or device selection for this patient?
— Disclosure already made? Disclosure mitigates but does not eliminate COI — management (recusal, divestiture) is often still required
— "The company sponsors all the meals at our weekly conference"
— "The physician failed to disclose…"
— "The drug sales rep provides samples that the physician gives to uninsured patients" (still creates bias toward branded over generic)
— "The journal editor owns stock in…"
Key distinction: Gifts to the physician personally (meals, travel, cash) are the highest-risk category. Educational materials of direct patient benefit (anatomic models, validated screening tools) are lower-risk if modest. Drug samples seem benign but bias toward expensive branded agents and bypass formulary safeguards — Step 3 treats them as a soft red flag, not as a generous workaround for cost.
— Axis 1 — Nature of the secondary interest: financial (gift, fee, equity, royalty), non-financial (career advancement, friendship, ideology)
— Axis 2 — Magnitude: trivial, modest, substantial, controlling (equity, royalties on prescribed device)
— Axis 3 — Probability of influence: direct (prescriber receiving drug-specific gift) vs remote (departmental grant unrelated to clinical decisions)
— Axis 4 — Severity of potential harm: to individual patient, to research integrity, to institutional trust, to public health
— Is there an institutional COI policy? Most academic centers and the AAMC require disclosure of payments >$5,000/yr from any single entity
— Is there an independent oversight body (IRB, COI committee, compliance office)?
— Is the physician in a fiduciary leadership role (department chair, formulary committee, guideline author)?
— Non-disclosure to patients, institution, or journal
— Ghostwriting or undisclosed authorship by industry employees
— Speaker bureau participation with sponsor-controlled slides
— Self-referral patterns where the physician profits from ordered services
— Research contracts giving sponsors right to suppress unfavorable results
Step 3 management: When the stem describes any of these "unstable" signs, the expected next step is disclose to the institutional COI office (or IRB, or journal editor) and recuse from the relevant decision. "Continue but try to remain objective" is virtually never the correct answer. Treat undisclosed industry payments the way you would treat an untreated arrhythmia — identify, document, and intervene before harm occurs.
— All payments, gifts, meals, travel, and in-kind transfers from industry in the past 12 months
— All equity holdings, royalties, patents, and licensing agreements
— All consulting, advisory board, speaker bureau, and expert witness arrangements
— Family members' financial ties to relevant companies
— Generally acceptable: modest meals at independent CME, educational items of direct patient benefit <~$10–25, unrestricted educational grants vetted by institution, reimbursement for legitimate consulting at fair market value with written contract
— Acceptable only with disclosure and management: consulting, advisory boards, research funding, royalties — disclose to institution, patients when relevant, and journals
— Generally unacceptable: cash, personal gifts, entertainment, recreational travel, lavish meals, gifts tied to prescribing volume, ghostwriting, sponsor control over publication
— CMS Open Payments database (public, searchable by physician name)
— Institutional COI office thresholds (often $5,000/yr or any equity in a non-publicly traded relevant company)
— Journal ICMJE disclosure form for any publication
— Specialty society guideline panel rules (many now exclude conflicted members from voting)
— Annual institutional disclosure
— Per-protocol IRB disclosure for research
— Manuscript-level disclosure
— Patient-level disclosure when a financial interest could plausibly affect the recommendation (e.g., enrolling a patient in your own funded trial; using a device on which you receive royalties)
Board pearl: Disclosure is necessary but not sufficient. A common distractor is "disclose the relationship and proceed." For high-magnitude COIs (equity, royalties on the device being used, formulary voting), the correct answer adds recusal, divestiture, or management plan, not disclosure alone.
— Sponsor's role: Did the sponsor design the protocol, control data analysis, or retain veto power over publication? ICMJE requires authors to attest to independent access to data and final authority over manuscript content.
— Equipoise: Is the PI's financial interest large enough to compromise clinical equipoise? Equity in the sponsor or royalties on the study drug typically disqualify a physician from being the treating investigator.
— Informed consent: Federal regulations and most IRBs require disclosure of significant financial interests to research subjects (e.g., "the principal investigator holds stock in the company manufacturing this drug").
— National Academy of Medicine recommends that chairs of guideline panels have no relevant COI, and that conflicted members abstain from voting on affected recommendations.
— P&T (Pharmacy & Therapeutics) committee members typically must disclose and recuse from votes on products of companies with which they have ties.
— ACCME Standards for Integrity and Independence require that CME content be free of commercial bias, that planners and faculty disclose relevant financial relationships from the prior 24 months, and that ineligible-company employees not control content.
— A sponsored "dinner program" with scripted slides is promotional, not CME — even if a physician speaker is paid.
— Designated health services (imaging, PT, clinical lab, DME, etc.) referred by a physician to an entity with which they (or immediate family) have a financial relationship are prohibited unless a specific safe-harbor exception applies (e.g., in-office ancillary services with strict conditions).
Key distinction: Stark Law is strict liability and civil — intent does not matter. Anti-Kickback Statute requires intent to induce referrals but is criminal, with felony penalties. Both apply primarily to federal payors (Medicare/Medicaid); many states have parallel laws covering all payors.
— Patient-care items of nominal value (anatomic charts, validated screening tools, textbooks) <~$25
— Modest meals at genuinely independent CME accredited by ACCME
— Reimbursement at fair market value for legitimate consulting work documented by written contract, with deliverables and time tracking
— Research funding from industry — manage via IRB, institutional COI office, independent data monitoring, and protocol-level disclosure to subjects
— Consulting/advisory roles — disclose annually, recuse from institutional decisions about the sponsor's products
— Royalties on a device — disclose to every patient in whom the device is used; consider having a partner perform the procedure when feasible
— Personal gifts, cash, entertainment, recreational travel
— Equity in a non-publicly-traded company whose product the physician studies, prescribes, or recommends in guidelines
— Speaker bureau participation with sponsor-controlled content (increasingly viewed as promotional, not educational)
— Any arrangement tied to volume or value of referrals or prescriptions (per-prescription bonuses) — illegal under Anti-Kickback
— Would a reasonable patient feel deceived if they learned of this arrangement? If yes → refuse or fully disclose and manage.
— Could this arrangement be reported on the front page of a newspaper without embarrassment? If no → refuse.
— Does this arrangement affect a specific patient's care decision? If yes → disclose to the patient.
Step 3 management: The highest-yield rule is: a physician should not accept any gift, payment, or arrangement that could reasonably be perceived as influencing patient-care decisions, and must disclose any relationship that does exist to patients, institutions, and journals as relevant. When in doubt, the exam-correct action is to decline and document.
— Marketed as helping uninsured patients, but evidence shows samples are disproportionately given to insured patients and shift prescribing toward expensive branded agents even when generics are equivalent.
— Bypass formulary safeguards, drug interaction screening, and pharmacist counseling.
— Many academic centers and integrated systems (Kaiser, VA, Cleveland Clinic, many AMCs) ban samples entirely.
— Alternatives for cost-constrained patients: patient assistance programs, $4 generic lists, GoodRx, 340B pricing, federally qualified health centers.
— Even brief rep contact measurably increases branded prescribing and decreases adherence to evidence-based guidelines.
— Accepting meals from a manufacturer is associated with increased prescribing of that manufacturer's drug — dose-response relationship demonstrated in Medicare Part D data.
— Best practice (and most institutional policy): no rep access without appointment, no meals, no samples, no branded items, academic detailing preferred.
— Speakers are paid (often $1,000–5,000/event) to present sponsor-prepared slides — this is promotional activity, not independent education or consulting.
— Increasing institutional bans on faculty participation; OIG has flagged speaker bureaus as high-risk under the Anti-Kickback Statute when payments exceed fair market value or are tied to prescribing.
— Industry-funded CME must comply with ACCME standards: separation of commercial supporter from content, disclosure of all relationships, no product promotion.
— Prefer commercial-support-free CME when available; document independent content control if industry-supported.
Board pearl: When a vignette asks how to provide medications to an uninsured patient, the correct answer is patient assistance program or generic substitution, not "give samples." Samples are framed on the exam as a marketing tool, not a safety net.
— Surgeons who invent or improve devices may legitimately receive royalties, but must disclose the financial interest to every patient in whom the device is used as part of informed consent.
— Royalties may not be tied to the inventor's own use of the device (OIG guidance) — must be based on others' adoption.
— When feasible, a non-conflicted partner should perform the case, or an independent surgeon should obtain consent.
— Entities through which physicians profit from devices they implant — OIG has identified these as inherently suspect under the Anti-Kickback Statute.
— Permitted under Stark in-office ancillary services exception only if strict conditions are met (same building, supervision, billing rules). Self-referral patterns still warrant scrutiny for over-utilization.
— Recruitment bonuses, productivity incentives, and medical directorships must be at fair market value and not tied to referral volume for federal payors.
— Joint ventures (ASCs, imaging centers) require careful structuring under Stark/AKS safe harbors.
— When a PI has equity in the sponsor, most institutions require: (1) disclosure to subjects in consent, (2) appointment of an independent monitor or co-investigator, (3) sometimes divestiture or removal as PI.
— Industry-sponsored trials must guarantee investigators' right to publish results regardless of sponsor preference (ICMJE requirement).
— Must be in writing, specify deliverables, pay fair market value, track hours, and be reportable under Sunshine Act.
CCS pearl: In a CCS-style scenario where you're consulted about a colleague's industry arrangement, the high-yield orders are: "refer to institutional COI office," "notify IRB" (if research), and "recuse from formulary/guideline vote" — analogous to ordering the right consult and stopping the offending agent.
— AAMC and ACGME strongly discourage trainee acceptance of industry gifts, meals, and rep contact. Many programs prohibit rep access to training areas.
— Trainees are particularly vulnerable: behavioral patterns established in training persist; even small gifts during residency correlate with branded prescribing years later.
— Faculty have a professional duty to model COI-free behavior and to teach explicit COI curriculum (ACGME milestones in professionalism).
— Student loan burden and modest starting salaries create vulnerability to speaker bureau and consulting offers. Step 3 expects recognition that financial pressure does not justify accepting arrangements that compromise objectivity.
— Academic promotion increasingly weighs integrity of disclosure as part of professionalism review.
— Common scenario: retired physician joins a company's advisory board or accepts paid speaking. Acceptable if disclosed, fair market value, and no ongoing patient care decisions are affected. Still must be reported under Sunshine Act if licensed.
— Department chairs, P&T committee members, IRB members, guideline panel chairs, and formulary directors are held to the strictest standard — even modest industry ties may require recusal or stepping down.
— Journal editors must disclose all relationships; many top-tier journals require editors to have no industry ties during their tenure.
— FDA limits advisory committee membership for investigators with financial interests >$50,000 in a relevant company; waivers are public.
Key distinction: The higher the physician's institutional decision-making authority, the lower the threshold for problematic COI — analogous to dose-adjusting in renal failure. A modest consulting fee that is acceptable for a community internist may be disqualifying for the chair of the national guideline panel on that disease.
— Industry marketing of infant formula, ADHD medications, and adolescent vaccines raises heightened ethical concern given inability of pediatric patients to evaluate or consent to influenced recommendations.
— AAP and IHS Code restrict formula marketing in newborn nurseries; many hospitals have banned formula gift bags.
— Industry promotion of specific contraceptives, prenatal vitamins, or fertility drugs to obstetricians is subject to standard COI rules; no special exception.
— Small, symbolic gifts (homemade food, handmade items, modest tokens of gratitude) — generally acceptable to decline politely or accept graciously depending on cultural context.
— Substantial gifts (cash, expensive items, vacations, inheritance, naming the physician in a will) — generally decline; risk of impaired objectivity and exploitation, particularly with vulnerable or terminally ill patients.
— Sexual or romantic relationships with current patients are prohibited by AMA Code and most state medical boards — strict liability, separate from COI but tested in the same block.
— Some cultures place strong importance on gift-giving; a polite refusal can be offensive. Best practice: accept a token of nominal value, document, and decline larger gifts with explanation.
— Industry donations of drugs/devices to global health programs are common; ensure donations match local need, don't displace sustainable supply, and don't promote inappropriate use (e.g., expired medications, off-label promotion abroad).
— Physicians employed by DTC platforms (telehealth weight loss, hair loss, ED) must disclose any equity or per-prescription compensation; arrangements tied to prescribing volume are problematic.
Board pearl: A grateful patient offering a modest, symbolic gift is the classic distractor where "accept graciously" is correct. A patient writing the physician into their will is the classic distractor where decline and document is correct.
— Inappropriate prescribing: branded over generic, newer over established, off-label without evidence
— Overutilization of conflicted services (self-referred imaging, in-house labs, owned ASCs)
— Underutilization of competing effective therapies
— Direct safety harms when sponsor-controlled research suppresses adverse event data (rofecoxib/Vioxx, rosiglitazone, OxyContin marketing)
— Publication bias — industry-funded trials are more likely to report favorable results than independent trials of the same intervention
— Outcome switching, ghostwriting, selective reporting
— Erosion of clinical equipoise when investigators have financial stake in outcomes
— Loss of public trust in medicine, journals, and guidelines
— Distorted formularies and practice guidelines when conflicted authors dominate panels
— Inflated healthcare costs driven by branded prescribing
— Civil penalties under Stark (up to $15,000 per service, $100,000 per scheme)
— Criminal penalties under Anti-Kickback Statute (felony, up to 10 years, $100,000 fine per violation, exclusion from Medicare/Medicaid)
— State licensing board action, hospital privileging review
— Loss of academic position, retraction of publications, NIH funding suspension
— False Claims Act liability (treble damages) when conflicted referrals generate federal claims
— Opioid crisis as a paradigmatic example: industry marketing, paid speakers, ghostwritten "pseudoaddiction" literature, and suppressed risk data contributed to a generational catastrophe.
Step 3 management: When a complication scenario emerges (e.g., adverse outcome traced to a conflicted recommendation), the immediate steps are disclose to the patient, report to the institution and IRB if research-related, and cooperate with any compliance investigation — analogous to managing a medical error under transparency principles.
— Any single financial relationship exceeds the institutional threshold (typically $5,000/yr, or any equity in a private relevant company)
— A new arrangement is being considered that may affect patient care or research
— A colleague's undisclosed COI is suspected (peer reporting duty under medical ethics codes)
— A PI or co-investigator has a financial interest in the sponsor, drug, or device
— Sponsor seeks to alter protocol, suppress data, or modify consent in ways that may affect subjects
— Adverse events suggest the financial interest may have biased subject selection or assessment
— A previously undisclosed relationship is discovered after submission or publication — issue a correction or erratum
— Co-author conflicts emerge during peer review
— Possible Stark or Anti-Kickback violation
— Suspected illegal kickback (per-prescription bonus, sham consulting agreement)
— Whistleblower concerns — False Claims Act qui tam provisions protect and reward whistleblowers
— Physician misconduct involves patient harm, fraud, or unprofessional behavior beyond simple disclosure failures
— Recuse from formulary, guideline, P&T, IRB, or hiring decisions involving a company with which you have a relationship
— Recuse from patient care decisions involving a device on which you hold royalties when a partner is available
— Recuse from manuscript review where you have any direct or family financial tie to a competitor or to the sponsor
— Physicians have an ethical duty (AMA Code §9.4) to report colleagues whose undisclosed COI threatens patient welfare — first through institutional channels, then licensing bodies if unaddressed.
CCS pearl: "Notify institutional COI office" and "recuse from decision" are the equivalent of "call rapid response" — early, low-cost, and almost never the wrong answer on the exam.
— Resolution: patient interests primary; disclose dual role to patient (e.g., independent medical exams, fitness-for-duty evaluations are not therapeutic relationships and require explicit disclosure)
— Crossings (small, often acceptable: brief social pleasantry, attending a patient's funeral)
— Violations (sexual relationship with current patient, business partnerships with patients) — prohibited
— Discouraged except for minor self-limited conditions or emergencies — impairs objectivity and documentation, similar mechanism to COI
— Payment arrangements that reward withholding care (capitation with downside risk) are an inverse COI — physician benefits from doing less. Must be disclosed; cannot compromise medically necessary care.
— Paid testimony is acceptable if compensation is fair market value, opinion is based on review of evidence, and physician is qualified. Contingency-fee testimony is prohibited by AMA.
— Many disease advocacy groups receive substantial industry funding. Physicians serving on their boards should disclose this when citing their materials.
— Listing as author someone who did not contribute (gift authorship) or omitting industry writers who did contribute (ghost authorship) violates ICMJE criteria.
Key distinction: COI is a structural risk of bias regardless of whether bias actually occurs — it is managed by disclosure and recusal. Research misconduct (fabrication, falsification, plagiarism) is an act requiring investigation and sanction. Both can coexist but require different responses.
— Material financial interests of the treating physician are part of what must be disclosed for valid informed consent (per Moore v. Regents of UC and subsequent jurisprudence). A patient cannot truly consent to a recommended procedure without knowing the physician's royalty interest in the device.
— Separate domain (child/elder abuse, certain infectious diseases, gunshot wounds, impaired drivers in some states) — tested in same block but mechanism is statutory duty, not COI.
— Separate domain; relevant only when a conflicted physician is also the surrogate decision-maker for a patient (e.g., physician-family member of patient) — generally requires deferring to an unconflicted surrogate or ethics consultation.
— Separate domain, but COI can arise when a physician's compensation is tied to ICU length of stay or specific procedures.
— Separate domain; reporting impaired colleagues is a parallel professional obligation to reporting unmanaged COI.
— IRB review, informed consent for research, vulnerable populations, equipoise — COI is one element within a broader research-ethics framework.
— ACO and bundled-payment arrangements create financial incentives to reduce utilization — a structural COI managed through quality metrics, patient experience scores, and transparency.
— Legal in US (one of only two countries) but raises ethical concerns; physicians should evaluate patient-requested medications on evidence, not marketing exposure.
Board pearl: Step 3 ethics blocks commonly mix categories. Read each stem carefully: a vignette mentioning a drug rep, an uninsured patient, and a guideline recommendation may simultaneously test COI, samples, and evidence-based prescribing — the correct answer addresses the dominant ethical issue, usually COI.
— Maintain a personal disclosure log updated at least annually; reconcile with CMS Open Payments entries (errors are common; physicians can dispute incorrect entries).
— Use independent drug information sources (UpToDate, Cochrane, USPSTF, specialty society guidelines vetted for COI, The Medical Letter, Prescriber's Letter) rather than rep-provided information.
— Pursue commercial-support-free CME when available.
— Default to generic prescribing; require a specific clinical reason to choose branded.
— Eliminate rep access or set strict appointment-only, no-meal, no-sample policies.
— Written policy on rep interactions, sample handling, gift acceptance, and consulting/speaker arrangements
— Annual staff training on COI and Sunshine Act
— Designated compliance contact
— Annual disclosure to institution; update for any new relationship within 30 days
— Recuse proactively from formulary, P&T, hiring, and procurement decisions involving any company with which you have a relationship
— Support institutional bans on samples and on speaker bureau participation by faculty
— Pre-register trials on ClinicalTrials.gov
— Retain right to publish independent of sponsor
— Disclose all relationships on every manuscript and grant submission
— Use independent statisticians and data monitoring committees for industry-funded trials
— Anticipate transitions: moving from clinical practice to advisory roles, retirement from academia to consulting — each transition requires re-evaluation of obligations
— Maintain integrity of CV: do not omit industry relationships when applying for guideline panels, editorships, or leadership roles
— Plan succession of leadership roles so that conflicted members rotate off committees on schedule
Step 3 management: A COI-resistant practice is built the way secondary cardiovascular prevention is built — through standing systems (statins, BP control, antiplatelets ≈ disclosure logs, generic-first prescribing, no-rep policies) rather than case-by-case willpower. Systems beat intentions.
— Update institutional disclosure each year, plus within 30 days of any new relationship
— Reconcile against CMS Open Payments database (data refreshed annually each June for prior year)
— Reaffirm disclosure on each manuscript, grant, IRB submission, and guideline panel role
— Compliance with the management plan (e.g., recusal logs, co-investigator oversight, partner consent for royalty-bearing devices)
— Trend in prescribing or referral patterns relative to peers (institutional dashboards increasingly flag outliers)
— Patient complaints or adverse outcomes potentially linked to the relationship
— Continued fair market value of consulting payments — escalating fees without escalating deliverables is a red flag
— Initial review at relationship onset
— Annual reassessment
— Trigger-based review (new patient harm, new role, new product launch)
— Incorporate COI discussion into onboarding, annual compliance training, and case-based teaching
— Model transparent declination of inappropriate offers in front of trainees
— When a financial interest could affect a specific recommendation (royalty device, enrollment in PI's trial, referral to physician-owned facility), disclose plainly as part of informed consent: "I want you to know that I have a financial interest in this device/study/facility, and here's what that means for your decision."
— Offer second opinion or alternative provider when feasible
— Record disclosure conversations in the chart
— Maintain copies of consulting contracts, IRB approvals, and recusal records for at least 6 years (False Claims Act statute of limitations)
— Would I be comfortable if every payment I received were on the front page of the newspaper?
— Have any of my relationships grown beyond what I would have agreed to initially?
— Am I prescribing or referring differently than peers without a clinical reason?
Board pearl: Just as you re-check A1c every 3 months and LDL after starting a statin, you re-check COI disclosures annually and at every role transition. Step 3 rewards the answer choice that includes ongoing reassessment.
— Fidelity — physician's primary obligation to patient welfare (AMA Principle I, II)
— Beneficence and non-maleficence — biased recommendations can directly harm
— Justice — overprescribing branded drugs to insured patients while leaving uninsured underserved
— Respect for autonomy — patients cannot exercise informed choice without knowing their physician's financial interests
— Stark Law (42 USC §1395nn): self-referral prohibition, strict liability, civil
— Anti-Kickback Statute (42 USC §1320a-7b): criminal, intent-based, felony, $100,000/violation, exclusion from federal programs
— False Claims Act (31 USC §3729): treble damages for claims tainted by kickbacks; qui tam whistleblower provisions
— Sunshine Act / Open Payments (42 USC §1320a-7h): mandatory manufacturer reporting
— State laws: parallel and sometimes stricter (e.g., Minnesota, Vermont, Massachusetts have limits on industry gifts to physicians)
— Informed consent edge case: Surgeon plans to implant a device on which they hold royalties. Required action: explicit verbal and written disclosure of the financial interest as part of the consent process, documented in the chart; offer alternative providers if patient prefers.
— Transition-of-care risk: Patient discharged on a branded medication the inpatient team chose after sponsored teaching — outpatient physician must reassess for generic equivalent or formulary alternative, avoiding therapeutic disruption.
— Mandatory reporting analog: Suspected illegal kickback (e.g., sham consulting agreement to disguise referral payments) should be reported to institutional compliance and, if unresolved, to the OIG hotline; False Claims Act protects whistleblowers from retaliation.
— Sample handling: Expired or improperly stored samples can directly harm patients — many institutions ban samples partly for medication-safety reasons.
— Research subject safety: PI with equity in sponsor must disclose this in the consent form; failure can render consent invalid and expose subjects to harm.
Step 3 management: When the stem hints at any of these — undisclosed royalty, kickback structure, sample-driven prescribing, or research COI — the correct answer pairs patient disclosure with institutional/IRB notification, never silent continuation.
Board pearl: When two answer choices both seem ethical, choose the one that adds disclosure, recusal, or institutional notification to the more passive option.
— "A pharmaceutical representative arrives offering lunch for the office staff while discussing a new DOAC. Most appropriate response?"
— Correct: Decline; or accept only if consistent with institutional policy, no promotional content, and modest. Distractor: "Accept because it won't influence prescribing."
— Surgeon receives royalties on a spinal implant and plans to use it in the next patient.
— Correct: Disclose financial interest as part of informed consent; document; offer alternative provider if patient prefers. Distractor: "Use the device without disclosure because royalties are paid by the company, not the patient."
— PI owns 5% equity in the sponsor of a phase 3 trial.
— Correct: Disclose to IRB and subjects; institutional COI office determines management plan (often appoint independent monitor or co-PI; may require divestiture). Distractor: "Continue as PI because disclosure to IRB is sufficient."
— Patient cannot afford a hypertension medication; rep offers branded samples.
— Correct: Use generic alternative or patient assistance program. Distractor: "Provide samples indefinitely."
— Cardiologist invited to chair a national lipid guideline panel but has $30,000/yr in consulting fees from a PCSK9-inhibitor manufacturer.
— Correct: Disclose; either decline the chair role or divest the consulting relationship for the duration of the panel. Distractor: "Accept and disclose at the end of the guideline."
— Elderly patient offers physician $5,000 cash after a successful operation.
— Correct: Politely decline; explain professional norms; suggest charitable donation if patient wishes. Distractor: "Accept because it's freely offered."
— Partner is observed prescribing exclusively one manufacturer's products after frequent sponsored dinners; patients complain.
— Correct: Raise concern through institutional channels (compliance, COI office); escalate to medical board if unaddressed. Distractor: "Confront the colleague and take no further action."
Key distinction: When two options are "decline" and "decline and report to institution," choose the one with institutional notification if there is any pattern suggestive of policy violation or patient harm.
A physician's primary duty is to the patient, and any financial or non-financial relationship with industry that could reasonably appear to influence clinical, research, or educational judgment must be declined, disclosed, and actively managed — disclosure alone is rarely sufficient for high-magnitude conflicts.
Board pearl: The single most testable principle is that self-assessed objectivity is not a defense — Step 3 expects you to act on the appearance of bias, not on your confidence that you are unbiased.